重磅!全国肝病和艾滋病临床免疫与细胞治疗研讨会 即将召开

2017-09-29 MedSci MedSci原创

肝病和艾滋病是严重危害给我国社会造成了严重的影响。我们在多方面都取得了巨大的成就,但距离疾病的治愈还有不小的差距。为此,生物谷举办“全国肝病和艾滋病临床免疫与细胞治疗研讨会”,我国著名的细胞治疗专家、国家卫计委和食药总局相关部门负责领导前来参加会议,以求互相借鉴推动我国免疫细胞治疗的的临床研究和应用。一、嘉宾二、会议议题会议议题疑难肝病专题 - 肝病免疫学研究进展 -&nbsp



肝病和艾滋病是严重危害给我国社会造成了严重的影响。我们在多方面都取得了巨大的成就,但距离疾病的治愈还有不小的差距。

为此,生物谷举办“全国肝病和艾滋病临床免疫与细胞治疗研讨会”,我国著名的细胞治疗专家、国家卫计委和食药总局相关部门负责领导前来参加会议,以求互相借鉴推动我国免疫细胞治疗的的临床研究和应用。

一、嘉宾







二、会议议题

会议议题
疑难肝病专题 
- 肝病免疫学研究进展 
干细胞治疗疑难肝病的临床研究 
- 肝癌的细胞治疗研究

病毒性肝炎专题 
- 病毒性肝炎抗病毒治疗研究进展 
- 病毒性肝炎抗病毒联合细胞治疗的临床研究 
- 病毒性肝炎的临床治愈

艾滋病专题 
- 艾滋病免疫学机制研究 
- 艾滋病抗病毒治疗方案 
- 艾滋病机会性感染控制 
- 艾滋病细胞治疗的临床研究

细胞治疗政策和规范 
- 细胞制品管理标准与规范 
干细胞临床研究注册 
FDA细胞治疗管理思考

三、会议日程





四、注册收费


五、联系方式

参会和媒体合作:
  朱赛博
 E-mail: saibo.zhu@medsci.cn
 Mt: 15021269895

赞助和大会咨询:
  陈颖杰 Andrew Chen
 E-mail: yingjie.chen@bioon.com
 Mt: 13661419496

  谢建胜
 E-mail: jiansheng.xie@bioon.com
 Mt: 18360734019(微信同号)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797285, encodeId=57771e97285f8, content=<a href='/topic/show?id=c75822682d8' target=_blank style='color:#2F92EE;'>#临床免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22682, encryptionId=c75822682d8, topicName=临床免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 13 12:05:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994776, encodeId=37e41994e76b0, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Sep 29 20:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805358, encodeId=f8e21805358bf, content=<a href='/topic/show?id=0b7ee794769' target=_blank style='color:#2F92EE;'>#细胞治疗研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77947, encryptionId=0b7ee794769, topicName=细胞治疗研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Mar 27 09:05:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549189, encodeId=0ffb15491891a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 03:05:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248803, encodeId=431f248803ad, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:37 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797285, encodeId=57771e97285f8, content=<a href='/topic/show?id=c75822682d8' target=_blank style='color:#2F92EE;'>#临床免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22682, encryptionId=c75822682d8, topicName=临床免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 13 12:05:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994776, encodeId=37e41994e76b0, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Sep 29 20:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805358, encodeId=f8e21805358bf, content=<a href='/topic/show?id=0b7ee794769' target=_blank style='color:#2F92EE;'>#细胞治疗研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77947, encryptionId=0b7ee794769, topicName=细胞治疗研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Mar 27 09:05:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549189, encodeId=0ffb15491891a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 03:05:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248803, encodeId=431f248803ad, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:37 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 kcb069
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797285, encodeId=57771e97285f8, content=<a href='/topic/show?id=c75822682d8' target=_blank style='color:#2F92EE;'>#临床免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22682, encryptionId=c75822682d8, topicName=临床免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 13 12:05:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994776, encodeId=37e41994e76b0, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Sep 29 20:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805358, encodeId=f8e21805358bf, content=<a href='/topic/show?id=0b7ee794769' target=_blank style='color:#2F92EE;'>#细胞治疗研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77947, encryptionId=0b7ee794769, topicName=细胞治疗研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Mar 27 09:05:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549189, encodeId=0ffb15491891a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 03:05:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248803, encodeId=431f248803ad, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:37 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797285, encodeId=57771e97285f8, content=<a href='/topic/show?id=c75822682d8' target=_blank style='color:#2F92EE;'>#临床免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22682, encryptionId=c75822682d8, topicName=临床免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 13 12:05:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994776, encodeId=37e41994e76b0, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Sep 29 20:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805358, encodeId=f8e21805358bf, content=<a href='/topic/show?id=0b7ee794769' target=_blank style='color:#2F92EE;'>#细胞治疗研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77947, encryptionId=0b7ee794769, topicName=细胞治疗研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Mar 27 09:05:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549189, encodeId=0ffb15491891a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 03:05:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248803, encodeId=431f248803ad, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:37 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-10-01 xxxx1054
  5. [GetPortalCommentsPageByObjectIdResponse(id=1797285, encodeId=57771e97285f8, content=<a href='/topic/show?id=c75822682d8' target=_blank style='color:#2F92EE;'>#临床免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22682, encryptionId=c75822682d8, topicName=临床免疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 13 12:05:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994776, encodeId=37e41994e76b0, content=<a href='/topic/show?id=3d51e345936' target=_blank style='color:#2F92EE;'>#研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73459, encryptionId=3d51e345936, topicName=研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Sep 29 20:05:00 CST 2017, time=2017-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805358, encodeId=f8e21805358bf, content=<a href='/topic/show?id=0b7ee794769' target=_blank style='color:#2F92EE;'>#细胞治疗研讨会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77947, encryptionId=0b7ee794769, topicName=细胞治疗研讨会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Tue Mar 27 09:05:00 CST 2018, time=2018-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549189, encodeId=0ffb15491891a, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sun Oct 01 03:05:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248803, encodeId=431f248803ad, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Fri Sep 29 13:40:37 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 Y—xianghai

    学习了新知识

    0

相关资讯

Journal of Hepatology:小憩一会,喝杯茶,喝杯咖啡,还可预防肝病哦~

肝硬化或称慢性肝病,是一种严重疾病,已成为美国各地居民死亡的主要原因。为了预防肝脏疾病,一项最新研究推荐,我们可以休息一下,好好享用一杯茶。肝病相关性死亡往往是肝硬化的结果。虽然绝大多数人肝硬化病例是由于长期饮酒引起的,非酒精性脂肪肝(NAFLD)也可导致肝硬化。发表在《肝脏病学杂志》上的这项最新研究增加了一系列新的预防因素:茶和咖啡。以荷兰鹿特丹Erasmus大学医学中心肝病专家Sarwa Da

MOL METAB :酒精性肝病怎么治?研究发现重要新药线索!

饮酒过多酒精可能会损害肝脏,但调查人员发现可能有助于治疗酒精性肝病的保护性反应措施。 Beth Israel Deaconess医疗中心(BIDMC)的研究人员与宾夕法尼亚大学的同事合作组织的团队也发现,同样的保护措施可能与厌恶酒精有关,因此有助于治疗酒精中毒。

从医执教50周年|王吉耀:三代行医,医学是深入血液的基因

医学精神究竟如何传承,从她身上或许能找到答案。日前,专访复旦大学上海医学院内科学系主任、复旦大学循证医学中心主任、复旦大学附属中山医院消化科王吉耀教授,让老一辈医学家为我们口述历史。

酒精是肝病很大帮凶 莫让干杯变“肝悲”

2017年7月28日是第7个“世界肝炎日”。“肝炎日”的设立旨在不断提高公众尤其是高危人群对慢性肝病的认知和防控能力。中国是肝病大国,但是公众对肝病的症状、危害尤其是慢性肝病调养方面不了解,导致很多患者存在调养及日常管理方面的认识误区,从而贻误或加重病情,致使肝硬化、肝癌等严重后果的出现。7月18日,在上海举办的“莫让干杯变肝悲”专家沙龙活动中,上海交通大学医学院附属仁济医院消化内科主任医师、中华

肝病患者在夏季如何护理

首先要避免过度劳累,保证充足的睡眠。劳累会使机体免疫失衡,加重了肝脏的负担,容易引发慢性肝炎的复发。其次,不宜在空调房中停留太久,空调房中空气流动差,空气污浊,易滋生病菌,损伤肝脏,所以房间要定时通风,保持空气新鲜。所谓“久视伤肝,久坐伤骨”,经常看电脑、读书的人就具备了久视和久坐这两个条件。加之天气炎热户外活动减少,往往电脑、电视成了很多人消遣的一种方式,往往晚上过12点才睡。别以为体力劳动才会

BMJ:肝硬化筛查是否有必要?

最近的指导方针是建议筛查高危患者肝硬化,泰恩河畔纽卡斯尔的弗里曼医院的肝病专家马克·哈德森(Mark Hudson)和南安普敦综合医院的尼克·谢伦(Nick Sheron)说。